OBJECTIVE: Estrogen metabolites have been associated in the pathogenesis of breast and cervical cancer; 16alpha-hydroxyestrone(16alpha-OHE1) demonstrated proliferative effects whereas 2-hydroxyestrone(2-OHE1) had antiproliferative effects. Our study's objective is to demonstrate that head and neck (H&N) cancer patients metabolize estrogen differently than healthy controls, which may constitute a risk factor for H&N cancer development. STUDY DESIGN: Urinary metabolite levels of 2-OHE1 and 16alpha-OHE1 from 50 H&N cancer patients and 50 age- and sex-matched controls were measured using enzyme-linked immunosorbent assay (ELISA). Absolute values and 2-/16alpha-OHE1 ratios were calculated. Conditional logistic regression for univariate and multivariate analysis with odds ratio (OR) and 95% confidence interval (CI) were used. RESULTS: Thirty percent (15 of 50) from the case group had a low 2-/16alpha-OHE1 ratio compared with only 4% (2 of 50) in the control group (OR = 11.1; 1.4-91.5, 95% CI) (P < 0.05). When adjusted for tobacco, OR remained significant at 15.6 (1.1-212.5, 95% CI) (P < 0.05). CONCLUSION: H&N cancer patients are more likely to express abnormal estrogen metabolism than healthy controls; 2-/16alpha-OHE1 may serve as a potential biological marker of individuals at increased risk of H&N cancer.
OBJECTIVE: Estrogen metabolites have been associated in the pathogenesis of breast and cervical cancer; 16alpha-hydroxyestrone(16alpha-OHE1) demonstrated proliferative effects whereas 2-hydroxyestrone(2-OHE1) had antiproliferative effects. Our study's objective is to demonstrate that head and neck (H&N) cancerpatients metabolize estrogen differently than healthy controls, which may constitute a risk factor for H&N cancer development. STUDY DESIGN: Urinary metabolite levels of 2-OHE1 and 16alpha-OHE1 from 50 H&N cancerpatients and 50 age- and sex-matched controls were measured using enzyme-linked immunosorbent assay (ELISA). Absolute values and 2-/16alpha-OHE1 ratios were calculated. Conditional logistic regression for univariate and multivariate analysis with odds ratio (OR) and 95% confidence interval (CI) were used. RESULTS: Thirty percent (15 of 50) from the case group had a low 2-/16alpha-OHE1 ratio compared with only 4% (2 of 50) in the control group (OR = 11.1; 1.4-91.5, 95% CI) (P < 0.05). When adjusted for tobacco, OR remained significant at 15.6 (1.1-212.5, 95% CI) (P < 0.05). CONCLUSION: H&N cancerpatients are more likely to express abnormal estrogen metabolism than healthy controls; 2-/16alpha-OHE1 may serve as a potential biological marker of individuals at increased risk of H&N cancer.
Authors: Tram Kim Lam; Amanda J Cross; Neal Freedman; Yikyung Park; Albert R Hollenbeck; Arthur Schatzkin; Christian Abnet Journal: Cancer Causes Control Date: 2011-07-23 Impact factor: 2.506
Authors: Eva Remenár; Irén Számel; Barna Budai; Borbála Vincze; István Gaudi; Sarolta Gundy; Miklós Kásler Journal: Pathol Oncol Res Date: 2007-12-25 Impact factor: 3.201
Authors: Dana Hashim; Samantha Sartori; Carlo La Vecchia; Diego Serraino; Luigino Dal Maso; Eva Negri; Elaine Smith; Fabio Levi; Stefania Boccia; Gabriella Cadoni; Hung N Luu; Yuan-Chin Amy Lee; Mia Hashibe; Paolo Boffetta Journal: Cancer Med Date: 2017-07-14 Impact factor: 4.452
Authors: Dennis L Carter; Lina Asmar; David Barrera; John Caracandas; J Shaker Dakhil; Dean McCracken; Mark A O'Rourke; Richard K Rosenberg; Kristi A Boehm; Des Ilegbodu; Robert L Reid Journal: Invest New Drugs Date: 2008-05-13 Impact factor: 3.651